dexamethasone intravitreal implant


( Last Updated : May 9, 2022)
Generic Name:
dexamethasone intravitreal implant
Project Status:
Pending
Therapeutic Area:
Diabetic macular edema
Manufacturer:
Allergan, an AbbVie Company
Call for patient/clinician input open:
Brand Name:
Ozurdex
Project Line:
Reimbursement Review
Project Number:
SR0739-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with DME who are pseudophakic and have had an inadequate response to prior anti-vascular endothelial growth factors (VEGF) therapy.
Submission Type:
Resubmission
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic and have had an inadequate response to prior anti-vascular endothelial growth factors (VEGF) therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.